{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:32:58Z","timestamp":1771882378196,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00277-009-0820-9","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T13:39:44Z","timestamp":1251812384000},"page":"283-289","source":"Crossref","is-referenced-by-count":11,"title":["Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma"],"prefix":"10.1007","volume":"89","author":[{"given":"Andrea","family":"Borgerding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Hasenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Gla\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,2]]},"reference":[{"key":"820_CR1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den NE, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"820_CR2","first-page":"1492","volume":"106","author":"B Glass","year":"2005","unstructured":"Glass B, Kloess M, Reiser M, Metzner B, Truemper LH, Loeffler M, Pfreundschuh M, Schmitz N (2005) Dose escalated CHOP + etoposide followed by repetitive autologous stem cell transplantation (MegaCHOEP) with or without rituximab for primary treatment of aggressive NHL. ASH Annual Meeting Abstracts 106:1492","journal-title":"ASH Annual Meeting Abstracts"},{"key":"820_CR3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391","journal-title":"Lancet Oncol"},{"key":"820_CR4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105\u2013116","journal-title":"Lancet Oncol"},{"key":"820_CR5","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117\u20134126","journal-title":"J Clin Oncol"},{"key":"820_CR6","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1080\/10428190600926572","volume":"47","author":"UJ Mey","year":"2006","unstructured":"Mey UJ, Olivieri A, Orlopp KS, Rabe C, Strehl JW, Gorschlueter M, Hensel M, Flieger D, Glasmacher AG, Schmidt-Wolf IG (2006) DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B cell lymphoma: a matched-pair analysis. Leuk Lymphoma 47:2558\u20132566","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"820_CR7","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","volume":"14","author":"AD Zelenetz","year":"2003","unstructured":"Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH (2003) Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 14(Suppl 1):i5\u201310","journal-title":"Ann Oncol"},{"key":"820_CR8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","volume":"18","author":"T El Gnaoui","year":"2007","unstructured":"El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, Gaillard I, Divine M, Tabah-Fisch I, Reyes F, Haioun C (2007) Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B cell lymphoma not candidates for high-dose therapy. Ann Oncol 18:1363\u20131368","journal-title":"Ann Oncol"},{"key":"820_CR9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der LH, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540\u20131545","journal-title":"N Engl J Med"},{"key":"820_CR10","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","volume":"93","author":"A Martin","year":"2008","unstructured":"Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, Garcia-Sanchez P, Vazquez L, Nistal S, Requena MJ, Donato EM, Gonzalez JA, Leon A, Ruiz C, Grande C, Gonzalez-Barca E, Caballero MD (2008) R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study. Haematologica 93:1829\u20131836","journal-title":"Haematologica"},{"key":"820_CR11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2008.07383.x","volume":"143","author":"C Gisselbrecht","year":"2008","unstructured":"Gisselbrecht C (2008) Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol 143:607\u2013621","journal-title":"Br J Haematol"},{"key":"820_CR12","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordstrom M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundstrom C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687\u20132693","journal-title":"Blood"},{"key":"820_CR13","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105:2677\u20132684","journal-title":"Blood"},{"key":"820_CR14","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013\u20137023","journal-title":"J Clin Oncol"},{"key":"820_CR15","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Bock HP, Wandt H, Unterhalt M, Hiddemann W (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064\u20133071","journal-title":"Blood"},{"key":"820_CR16","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"820_CR17","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927\u20131932","journal-title":"Blood"},{"key":"820_CR18","first-page":"4707","volume":"108","author":"A Palacios","year":"2006","unstructured":"Palacios A, Navarrete M, Gallur L, Zuazu J, Barrenetxea C, Sanchez E, Lopez A (2006) Re-treatment with rituximab plus chemotherapy in patients with aggressive lymphoma treated previously with CHOP or CHOP-like combinations plus rituximab. ASH Annual Meeting Abstracts 108:4707","journal-title":"ASH Annual Meeting Abstracts"},{"key":"820_CR19","first-page":"517","volume":"110","author":"C Gisselbrecht","year":"2007","unstructured":"Gisselbrecht C, Schmitz N, Mounier N, Ma D, Trneny M, Hagberg H, Linch DC, Shpilberg O, Ketterer N, Glass B, Bosly A, Gill D, Gaulard P, Moskowitz C (2007) R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. ASH Annual Meeting Abstracts 110:517","journal-title":"ASH Annual Meeting Abstracts"},{"key":"820_CR20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","volume":"48","author":"R Weide","year":"2007","unstructured":"Weide R, Hess G, Koppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M (2007) High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 48:1299\u20131306","journal-title":"Leuk Lymphoma"},{"key":"820_CR21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03019.x","volume":"114","author":"JM Foran","year":"2001","unstructured":"Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ, Lister TA (2001) Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol 114:881\u2013883","journal-title":"Br J Haematol"},{"key":"820_CR22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2008.001024","volume":"94","author":"NA Johnson","year":"2009","unstructured":"Johnson NA, Leach S, Woolcock B, deLeeuw RJ, Bashashati A, Sehn LH, Connors JM, Chhanabhai M, Brooks-Wilson A, Gascoyne RD (2009) CD20 mutations involving the rituximab epitope are rare in diffuse large B cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 94:423\u2013427","journal-title":"Haematologica"},{"key":"820_CR23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1349-7006.2008.01005.x","volume":"100","author":"AM Maeshima","year":"2009","unstructured":"Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y (2009) Histological and immunophenotypic changes in 59 cases of B cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci 100:54\u201361","journal-title":"Cancer Sci"},{"key":"820_CR24","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","volume":"67","author":"AR Jazirehi","year":"2007","unstructured":"Jazirehi AR, Vega MI, Bonavida B (2007) Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 67:1270\u20131281","journal-title":"Cancer Res"},{"key":"820_CR25","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","volume":"98","author":"J Golay","year":"2001","unstructured":"Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98:3383\u20133389","journal-title":"Blood"},{"key":"820_CR26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-08-1685","volume":"15","author":"S Dalle","year":"2009","unstructured":"Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C (2009) In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res 15:851\u2013857","journal-title":"Clin Cancer Res"},{"key":"820_CR27","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1078-0432.CCR-1087-3","volume":"10","author":"WL Gluck","year":"2004","unstructured":"Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, Difrancesco A, Milan S, Wilson SE, Wolin M (2004) Phase I studies of interleukin (IL)-2 and rituximab in B cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 10:2253\u20132264","journal-title":"Clin Cancer Res"},{"key":"820_CR28","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","volume":"104","author":"G Cartron","year":"2004","unstructured":"Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104:2635\u20132642","journal-title":"Blood"},{"key":"820_CR29","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","volume":"64","author":"S Dall'Ozzo","year":"2004","unstructured":"Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64:4664\u20134669","journal-title":"Cancer Res"},{"key":"820_CR30","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","volume":"21","author":"WK Weng","year":"2003","unstructured":"Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940\u20133947","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0820-9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T22:53:34Z","timestamp":1590101614000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-009-0820-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,2]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["820"],"URL":"https:\/\/doi.org\/10.1007\/s00277-009-0820-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,2]]}}}